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Abstract
Introduction: Efficacy and safety are critical concerns when designing drug carriers. Nanoparticles are a particular
type of carrier that has gained recent attention in cancer therapeutics.
Methods: In this study, we assess the safety profile of IT-101, a nanoparticle formed by self-assembly of
camptothecin (CPT) conjugated cyclodextrin-based polymers. IT-101 delivers CPT to target cancer cells in animal
models of numerous human cancers and in humans. Previous data from preclinical and clinical trials indicate that
IT-101 has no notable immunological side effects. However, there have been no published studies focused on
evaluating the effects of IT-101 on host immune systems.
Results: In this work, we demonstrate that IT-101 diminished initial host immune response following first injection
of the nanopharmaceutical and induced NK cell activation and T cell proliferation upon further IT-101 exposure.
Additionally, IT-101 could attenuate tumor growth more efficiently than CPT treatment only.
Conclusions: Drugs administration in whole-body circulation may lead to poorly bioavailable in central nervous
system and often has toxic effects on peripheral tissues. Conjugated with cyclodextrin-based polymers not only
reduce adverse effects but also modulate the immune responses to elevate drug efficacy. These immune responses
may potentially facilitate actions of immune blockage, such as PD1/PDL1 in cancer treatment.
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Background
The immune system is responsible for much of the
body’s systemic response to and modulation in internal
and external environmental stimuli. All foreign entities,
biological or chemical, may interact with the immune
system to cause localized and/or systemic immune re-
sponses. Accordingly, entities that can stimulate or sup-
press the immune system warrant investigation.
Recently, nanoparticles have been investigated as an
emerging medical application, particularly for drug deliv-
ery, and claims of their ability to bypass attack by host
immune systems, or activating immune responses have
appeared [1–5]. Therefore, understanding the immune
response induced by engineered nanoparticles is a crit-
ical priority when evaluating preclinical or clinical trials
in the future [6–8].
IT-101 is an engineered nanoparticle consisting of
cyclodextrin-based polymer conjugate of camptothecin
(CPT) that is formed by self-assembly [3]. This nanopar-
ticle is highly soluble, has long circulating half-life in
mammals and selectively targets solid tumors [9, 10].
IT-101 has been used to target and inhibit tumor
growth, and has successfully been translated from ani-
mals (preclinical) to human (clinical) studies. IT-101 has
also been shown to prolong the survival rate xenograft-
bearing mice with a wide variety of human tumor types
[11] including human B cell lymphoma [12] and intra-
cranial U87MG glioma-bearing nude mice [13]. Add-
itionally, there are noticeable similarities in
pharmacokinetic (PK) data obtained from rats, dogs, and
humans [14], demonstrating that IT-101 is translatable
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from animals to human. The first phase 1/2a clinical
trial indicated the safety, pharmacokinetics and efficacy
of IT-101 treatment [14, 15]. Clinical evaluation of IT-
101-like nanoparticles continue in Phase II trials (name
changed to CRLX101 and more recently NLG207).
Nanoparticles may be able to provide high-efficiency so-
lutions to delivering different kinds of drugs to the target
sites in mammals, and thus, whether nanoparticles can syn-
ergistically or antagonistically affect immune responses is
an essential feature that requires further attention [16, 17].
Although previous reports have indicated that cyclodextrins
alone do not elicit immune responses [18], to date, there
has not been detailed studies on this topic for cyclodextrin
containing polymers, as well as no reports about the effects
of IT-101 on host immune systems. To understand the im-
mune effects of IT-101, we systematically analyzed the
changes in lymphoid and myeloid cell populations related
to innate and adaptive immune responses and the subse-
quent immune effects, such as cytokine secretion into
circulation upon dosing IT-101 in mice (we maintain the
IT-101 nomenclature as the materials used is more consist-
ent with the properties reported for IT-101 [3, 9–11].
Methods
Animals
The inbred FVB strain mouse is widely applied in cancer re-
search. FVB wild-type mice were bred in a specific-
pathogen-free facility. The mouse model with spontaneous
brain tumor, F1B-Taq transgenic mouse, was obtained from
Dr. Ing-Ming Chiu in National Health Research Institutes
(NHRI) [19]. Euthanasia was performed using CO2 inhal-
ation. The animal protocol was approved by the Institutional
Animal Care and User Committee of National Defense
Medical Center.
IT-101 nanoparticle
IT-101 is a polymeric nanoparticle composed of CPT cova-
lently conjugated to the linear, cyclodextrin-polyethylene
glycol (CD-PEG) copolymer, that self-assembles into nano-
particles. The synthesis and properties of IT-101 have been
reported previously [3, 9–11]. As a positive control, CPT
was dissolved in PBS with 2% dimethyl sulfoxide (DMSO,
Sigma). Both IT-101 and CPT were inoculated at 10mg/kg
(for IT-101 the amount is the CPT equivalents dosed) by
intravenous (i.v.) and intraperitoneal (i.p.) injection, respect-
ively, to 2- and 4-month-old mice. PBS and 2% DMSO in
PBS were used as negative controls.
Flow cytometry
Immune responses were analyzed by flow cytometry.
Four-month-old wild-type FVB mice were inoculated by
intravenous injection with PBS and IT-101 and intraper-
itoneal injection with DMSO and CPT, respectively, and
sacrificed for experimental manipulation. The cells in
peripheral blood, spleen and groin lymph nodes were
collected and resuspended in RPMI-1640 medium. After
washing twice with stain buffer (BD), cells from spleen
and lymph nodes (1 × 106) and 0.1 mL of peripheral
blood were conjugated with different antibodies (CD11b,
CD11c, CD3, CD4, CD45, CD8a, CD19, F4/80, Gr-1,
MHCII, NK1.1). All cells were passed through 100 μm
pore-size nylon mesh and analyzed by BD FACSVerse
flow cytometry.
Intracellular cytokine staining (ICS)
FVB mice were sacrificed after 9 days of i.v injection.
Peripheral blood was incubated with PMA (20 ng/ml)
plus ionomycin (1 μl /ml) (BioLegend Cat. No. 423301)
and monensin (BioLegend Cat. No. 420701) at 37 °C.
After 6 h, lysed cells and stained surface marker Ab for
T and NK cells (CD3 and NK1.1) for 20 mins at room
temperature, and then treated with fixation buffer (Bio-
Legend Cat. No. 420801) for 20 mins. Cells incubated in
Intracellular Staining Perm Wash Buffer (BioLegend Cat.
No. 421002) for 15 mins, and then performed intracellu-
lar staining for TNF-α, IFN-γ for 30 mins. The data were
detected by Flow cytometer (BD FACSVerse).
Cytokine assay
We used RayBio C-Series Mouse Cytokine Antibody Array
Kit (RayBiotech) to evaluate expression levels of various cy-
tokines. The antibody array was carefully removed from the
plastic packaging, and each membrane was placed into a
well of the incubation tray with 2mL of blocking buffer for
30 mins at room temperature. Blocking buffer was then re-
moved from each well, and the wells were incubated with
serum or plasma at 4 °C overnight. Following aspiration of
the samples from each well, 1mL of detection antibody was
applied for 2 h at room temperature followed by 2mL of
HRP-Streptavidin Concentrate for 2 h at room temperature.
Three washes were performed between each incubation
step. Detection buffer was added onto each membrane and
incubated for 2min at room temperature. Each array mem-
branes were observed and analyzed by a chemilumines-
cence imaging system. Calculated data values higher than
1.5 or lower than 0.6 indicated significantly difference be-
tween two groups, respectively.
ELISA
FVB mice were injected with IT-101 or solvent (PBS
buffer) intravenously; serum was harvested after 9 days
of treatment. Each group comprised of three mice.
TNFα and IFN-γ levels were measured by the LEGEND
Max ELISA Kit with Precoated Plates (430,907 and 430,
807, Biolegend). IL-10 was measured by the Interleukin-
10 Mouse ELISA Kit (ab100697). The results were ana-
lyzed using a Synergy H4 Reader (Bio Tek Instruments).
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Histopathological analysis
After mice were anesthetized with 0.4–0.6mL avertin, we
harvested brain by perfusion with 10mL 4% paraformal-
dehyde and fixed half-brain by 10% formalin. Paraffin-
embedded samples slides were subjected to hematoxylin
and eosin (H&E) staining. Tissue sections were also sub-
jected to immunohistochemistry (IHC). The IHC staining
was performed by incubating sections with primary anti-
bodies targeting CD3 (ab5690, 1:100, abcam) for 18–24 h
at 4 °C, and then performed using biotinylated secondary
antibodies and an LSAB Kit (DakoCytomation). Sections
were observed by microscopy (Olympus IX73). Tumor
size was measured by software (SPOT Imaging).
Statistical analysis
Student’s t-test was performed using GraphPad Prism5
software with significance set at P < 0.05. Data are pre-
sented as the mean ± SD for all treatments.
Results
Innate immune response modulated by IT-101
To detect the natural immune response in mice treated
with IT-101 and CPT, the mice were inoculated and ana-
lyzed 16 h later (Additional file 1: Fig. S1a). Vehicles for
both agents were used as controls, namely PBS for IT-101
and DMSO for CPT. We analyzed the proportion of
leukocyte subtypes, as described in Additional file 1: Fig.
S1b, based on their major surface markers. We observed
lymphoid and myeloid cell lineages in peripheral blood,
spleen and groin lymph nodes. We analyzed myeloid cell
populations, such as immature dendritic cells (iDCs), neu-
trophils and macrophages. After CPT treatment, iDC and
neutrophil proportion in all three locations were dramat-
ically increased; meanwhile, the population of macro-
phages was decreased in the circulation (Fig. 1a-c).
Additionally, the proportion of neutrophils was signifi-
cantly decreased in the peripheral blood of mice after IT-
101 treatment. No noticeable difference in other myeloid
cell subtypes in peripheral lymph organs was observed
(Fig. 1a-c; Additional file 1: Fig. S2). The subtypes of
lymphoid cells included cytotoxic T lymphocytes (Tc
cells), helper T lymphocytes (Th cells), B lymphocytes (B
cells) and natural killer cells (NK cells). There was no not-
able difference in the lymphoid cell populations among
mice treated with IT-101, CPT and their controls (Fig. 1d-
f). Overall our data suggest that IT-101 reduces a select
myeloid cell population and this may modulate host im-
mune response when injected in FVB mice.
Cytokine analysis after one-dose of IT-101: inhibition of
inflammatory responses
We examined the expression levels of various cytokines in
peripheral blood following IT-101 exposure to determine
potential changes in host inflammatory response. Serum
collected from FVB mice treated with IT-101 and control
(PBS) was analyzed by independent cytokine assays (Add-
itional file 1: Fig. S3). After IT-101 treatment, the expression
Fig. 1 Innate immune responses at 16 h post induction by the
nanoparticle IT-101. (a)-(c) Changes in the proportions of cells in the
myeloid cell lineage, including iDCs, neutrophils and macrophages,
in peripheral blood, spleen and groin lymph nodes. (d)-(f) Changes
in the proportions of cells in the lymphoid cell lineage, including Tc,
Th, B and NK cells, in peripheral blood, spleen and groin lymph
nodes. Number of mice per group: 3–6 mice. The results are
presented as the mean ± SD. *p < 0.05; **p < 0.005; ***p < 0.0001
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levels of several chemokines were increased; these chemo-
kines include CXCL11 (I-TAC), CXCL12 (SDF-1), CXCL13
(BLC), CXCL10 (CRG-2) and CXCL16, that attract NK cells
and probably other cells, as well as soluble CD30 ligand
(sCD30L; TNFSF8), soluble CD30 (sCD30; TNFRSF8), and
soluble CD40 (sCD40; TNFRSF5), that interfere with T or B
cell functions (Fig. 2; Table 1). In addition to avoiding severe
inflammation, one injection of IT-101 decreased the
Fig. 2 Changes in cytokine expression after IT-101 nanoparticle treatment. Heat map showing the increase or decrease in cytokine levels after IT-
101 nanoparticle treatment. RayBio C-Series Mouse Cytokine Antibody Array Kit (RayBiotech) was used to evaluate expression levels of various
cytokines. Array I is the probed membrane for RayBio C-Series Mouse Cytokine Antibody Array C3 (monitoring 62 mouse proteins). Array II is the
probed membrane for RayBio C-Series Mouse Cytokine Antibody Array C4(monitoring 34 mouse proteins)
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expression levels of TNFα and its receptors, TNFRI
(TNFRSF1A) and TNFRII (TNFRSF1B) (Fig. 2; Table 1).
We noted that IT-101 treatment seemed to inhibit inflam-
mation and that further downstream immune responses
were inhibited following the first immunization with IT-101.
We also examined the expression levels of various cytokines
in peripheral blood following CPT exposure for analyzing
the potential differences between IT-101 and CPT in host
inflammatory response. Serum collected from FVB mice
treated with CPT and control (DMSO) was analyzed by in-
dependent cytokine assays (Additional file 1: Fig. S4). After
CPT treatment alone, trend change of several cytokines
were similar to samples with IT-101 treatment, such as Lep-
tin, RANTES (CCL5), SCF, CXCL11 (I-TAC), CXCL12
(SDF-1) and OPN; meanwhile, trend change of some cyto-
kines were opposite to samples with IT-101 treatment, such
Table 1 Quantified data for expression levels of cytokines and other secreted factors. Assay_I. *Values in red indicate cytokine
expression level was more than 1.5x control expression level after IT-101 exposure. Values in blue indicate cytokine expression level
was less than 0.6x control expression level after IT-101 exposure
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as CD30, CD40, CXCL10 (CRG-2), CXCL16, Eotaxin-1 and
MMP-3. Except above mentioned, CPT treatment also
modulated significant changes of various cytokines or sol-
uble factors, especially elevating CXCL, CCL, MMP, growth
factor and several immune-regulated factors. Altogether, our
data suggest that IT-101 seems to provide a barrier avoiding
the severe inflammatory responses after first immunization
with CPT.
Adaptive immune response induced by IT-101: increases
of NK cell and T cell populations
In addition to innate immunity, we also measured indica-
tions of the adaptive immune responses following IT-101-
and CPT-boosted treatment. Reinjection of CPT elevated
the proportion of neutrophils in blood circulation and
spleen, that caused a decrease in immature DC cells in
peripheral blood (Fig. 3a-c; Additional file 1: Fig. S5a-b).
Intriguingly, in peripheral blood and spleen, IT-101-
boosted treatment enhanced the NK cells and slightly in-
creased DCs in peripheral blood and lymph node, as well
as increased the total T cell proportion and the Tc cells.
(Fig. 3d-g; Additional file 1: Fig. S5c-e).
We summarized the effects of IT-101 and CPT on dif-
ferent immune cell populations after 16 (one dose) and
216 (one dose with booster doses) hours of treatment
(Table 2). The single-dose CPT treatment significantly
increased the proportions of neutrophils and immature
DCs, both of which mainly participate in the innate im-
mune response. IT-101 treatment with a single dose plus
booster doses markedly increased the proportion of NK
cells and total T cells. These results lead us to determine
the expression levels of NK cell-secreted cytokines in
blood circulation. Indeed, levels of the proinflammatory
cytokine TNFα and the T cell-activating cytokine INF-γ
were noticeably increased; meanwhile, the immune-
inhibitory cytokine IL-10 showed no significant differ-
ence between the IT-101- and control (PBS)-treated
groups (Fig. 4a). TNFα-positive T and NK cells were de-
tected in peripheral blood and spleen, and increased
INF-γ-positive T cells were observed in peripheral blood
after IT-101 treatment. (Fig. 4b-c). Therefore, we ob-
served that IT-101 enhances the proportion and activa-
tion of NK cells to facilitate T cell activation and
dendritic cell migration, rather than initiating innate im-
mune responses.
IT-101 efficiently attenuated tumor growth in mice
To verify whether cyclodextrin-based polymer can facili-
tate CPT to inhibit tumor growth, we treated a mouse
model bearing spontaneous brain tumor with IT-101,
CPT and their control solvents respectively. The average
lifespan of F1B transgenic mice was around 6months.
More than 50% of 2-month-old and almost all of 4-
month-old F1B transgenic mice had obvious tumors in
tegmental area of brain (Additional file 1: Fig. S6). CPT
treatment at early stage of tumorigenesis (2 months of
age) could significantly attenuate the tumor growth, and
notably IT-101 treatment had higher inhibitory effect on
tumorigenesis (Fig. 5a-b). However, at late stage of
tumorigenesis (4 months of age), IT-101 also had a
chance to attenuate the tumor growth, and only CPT
treatment had no significant effect on tumorigenesis
(Fig. 5c-d).
Discussion
Cancer immunotherapy is becoming commonplace for
standard cancer treatment. However, solid tumors can
shape an immunosuppressive tumor environment to by-
pass anticancer immune responses. Recent studies in
translational research have highlighted nanoparticles as
an emerging treatment modality for cancer. Various
biomaterial-based nanoparticles have been applied to
improve therapeutic efficacy, specificity, and stability.
Nanoparticles can have prolonged half-life to enable the
circulation of nanoparticle-delivered drugs to the whole
body. Moreover, nanoparticles have the potential advan-
tage of targeting specific cell types within target organs.
However, there have been concerns regarding the safety
of nanoparticles; thus, the toxicity, hazards, and immune
responses related to nanoparticles have become safety is-
sues of importance [6, 20].
Here, we demonstrated that IT-101, a nanoparticle
drug, did not induce non-specific inflammation, but ac-
curately altered the status of immune surveillance. First
immunization of IT-101 modulated an increase of im-
mature dendritic cells in lymphoid organs and a de-
crease of neutrophils in peripheral circulation,
companying with several cytokines or specific factors in-
duction. As previous reports, IT-101 has long PK and
better area under the curve (AUC) to continuously those
immune responses [14]. Subsequently, boost injection of
IT-101 induced effected NK cells and T cells to secrete
IFNγ and TNFα. TNFα might induce dendritic cell mi-
gration, and IFNγ can promote Th and Tc cell activa-
tion. These effects may enhance the function of effected
NK cells and exert anti-tumor function (Fig. 6). Both NK
and Tc cells can generate and secrete perforins and
granzymes to weaken and destroy tumor cells [21, 22].
Thus, the action of CPT may work together with these
effects to inhibit tumor growth.
After one-dose injection, CPT induced complicated
immune responses comparing to IT-101 treatment. Our
data showed that iDC and neutrophil proportion in all
three locations were obviously increased in CPT-treated
group, and indeed, the factors, which are responsible for
recruiting, activating and mediating activity for iDCs and
neutrophils, were elevated expressed in peripheral
lymphoid organs. These soluble factors include GM-
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CSF, MMP, TNF, IGF, IL-7, IL-15, IL-17, resistin, CCL2,
CCL22, CXCL7, VEGF, TSLP, TIMP and other undeter-
mined factors. However, CPT conjugated cyclodextrin-
based polymers could avoid from side effects of compli-
cated immune responses, and modulate the adaptive im-
mune responses after boosting.
Although some proinflammatory factors or neutrophil-
attracting factors, such as MMP3, CCL5, leptin and VEGF-
A, were decreased in the IT-101-treated group, other factors
like sCD30, sCD30L, sCD40 and sCD40L (that are reported
inflammatory markers in cancer patients), were elevated in
the circulation of IT-101-treated mice. In ovarian cancer pa-
tients, an increase in sCD30, sCD30L and sCD40 could be
early diagnostic indicators, and all of these factors may im-
pair apoptosis and interrupt the immune response [23]. The
expression levels of sCD30, as well as sCD30L, in circulation
could also be used as a prognostic marker for Hodgkin
lymphoma [24–26]. High levels of sCD40 have been found
associated with advanced pathogenesis and poor prognosis
in non-small cell lung cancer patients [27]. Similarly, reports
have showed high levels of sCD40L in patients with neopla-
sia and nasopharyngeal carcinoma (NPC); hence, sCD40L
might be a prognostic biomarker for NPC [28, 29]. Add-
itionally, sCD40L could be a diagnostic marker for hepatitis
C virus-related hepatocellular carcinoma [30]. The CD40/
CD154 interaction plays critical functions in humoral and
cellular immune responses. Elevated levels of the soluble
form of CD40 (sCD40) have been observed in patients in
uremic or hemodialyzed situations; of note, sCD40 is able to
inhibit immunoglobulin generation from CD154-induced
activated B cells [31].
Previous reports have indicated that specific antibodies
against PEG-coated liposomes could be generated to elim-
inate PEG-coated liposomes in circulation throughout the
whole body; however, accelerated blood clearance caused
by PEGylated liposomes was demonstrated to be due to
doxorubicin encapsulation and a high-dose first injection
[32, 33]. These antibodies have high potential to affect the
safety and efficiency of therapeutics. However, after re-
peated injections of IT-101, we detected no notable in-
crease in the proportion of B lymphocytes and T helper
cells. We therefore suggest that IT-101 injection has no or
low humoral immunogenicity.
Fig. 3 Adaptive immune responses after the second stimulation by
the nanoparticle IT-101. (a)-(c) Changes in the proportions of cells in
the myeloid cell lineage, including iDCs, neutrophils and
macrophages, in peripheral blood, spleen and groin lymph nodes.
(d)-(f) Changes in the proportions of cells in the lymphoid cell
lineage, including Tc, Th, B and NK cells, in peripheral blood, spleen
and groin lymph nodes. (g) Quantification of total T cells, labeled
with CD3 and CD45, in peripheral blood, spleen and lymph node.
(h) Increased T lymphocytes were observed in spleen after IT-101
treatment. Number of mice per group: 3–6 mice. The results are
presented as the mean ± SD. *p < 0.05; **p < 0.005; ***p < 0.0001
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Table 2 Summary for innate and adaptive immune responses after IT-101 and CPT treatment
Fig. 4 The expression levels of activated cytokines and inhibitory cytokines after IT-101 treatment. (a) The expression levels of IFN-γ, TNF-α and IL-
10 were detected after IT-101 treatment. (b) Higher proportion of TNF-α- and IFN-γ-secreted T cells and NK cells were observed in peripheral
blood after IT-101 treatments. (c) Higher proportion of TNF-α-secreted T cells and NK cells were observed in spleen. Mouse number per group, 3
mice. The results are presented as the mean ± SD. *p < 0.05; **p < 0.0005
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A recent study revealed local injury promotes activated
leukocyte infiltration and that these leukocytes further
secrete chemokines to induce activated NK cell recruitment
[34]. CXCR3 and CXCR4 are primarily expressed on
activated NK cells. CXCR3 expressed on NK cells
(CD56highCD27 high) facilitates enhanced proliferation and
cytokine production [35]. Various organ/tissue-specific dis-
eases caused by increased inflammation, such as chronic
hepatitis C virus infection, biliary cirrhosis, psoriatic and
osteoarthritis, attract NK cells via the CXCR3/CXCL10 axis
[36–39]; meanwhile, CXCL11-targeted CXCR3 promotes
antitumor responses [40]. The CXCR4/CXCL12 axis play an
important role in NK cell development in adults [41]. Rather
than assisting NK-mediated immune surveillance against
tumor formation and metastasis, some reports have indi-
cated that CXCR3- and CXCR4-mediated attraction of NK
cells may impede immune responses [42, 43]. In our study,
CXCL11 and CXCL12, whose secretion by peripheral blood
leukocytes was increased after IT-101 treatment, interacted
with CXCR3 and CXCR4, respectively, further increasing
the proportion of activated NK cells after repeat injections
and indicating that IT-101 nanoparticles could facilitate the
initiation of immune responses through chemotactic axes.
Here, we found that IT-101 could effectively bypass the
induction of innate immune responses and increase NK
cell activation after boost injection. NK cells have been re-
ported in humans and mice to antagonize virus infection
and tumor immunosurveillance [44]. NK cells are innate
cytotoxic lymphocytes that kill infected cells or tumor
cells via secreting lytic granules containing perforin and
apoptosis-inducing granzymes, and release cytokines or
secreted factors for inflammation and immunoregulation
[45, 46]. In the presence of stressed cells, DC maturation
is promoted by NK cell-derived IFN-γ and TNF-α. Subse-
quently, NK cells secrete IFN-γ to activate T cells and
macrophages and, in contrast, secrete IL-10 to dampen
the functions of T cells and macrophages. Therefore, NK
cells facilitate and enhance the antigen-presenting capacity
of immune cells and further regulate immune cells by se-
creting different cytokines, as NK cells participate in both
Fig. 5 IT-101 attenuated the brain tumor growth at early stage of tumorigenesis. (a) (b) 2-month-old F1B transgenic mice were treated with IT-
101 and PBS respectively by intravenous injection, one dose with booster doses. After two months ago, the tumor size was measured using
histopathological data. (c) (d) 4-month-old F1B transgenic mice were treated with IT-101 and PBS respectively by Intraperitoneal injection, one
dose with booster doses. After two months ago, the tumor size was measured using histopathological data. Mouse number per group, 3–5 mice.
The results are presented as the mean ± SD. *p < 0.05; **p < 0.005
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innate and adaptive immunity [47]. In humans and mice,
NK cells are recruited into draining lymph nodes and pro-
mote an adaptive immune response through the CXCR3-
CXCL10 axis; the attracted NK cells then provide IFN-γ,
which is necessary for dendritic cell modulation and T
helper cell polarization [48]. IFN-γ and TNF-α stimulate
various cells to induce CXCL10 elevation, resulting in re-
cruitment of Type 1 T helper cells [49]. Data from our
study suggests IT-101 has the potential to activate NK
cells to inhibit tumor spread and induce subsequent im-
munity by secreting activated cytokines such as IFN-γ and
TNF-α.
Conclusions
Based on our findings, boost injection of IT-101 could
regulate NK cell activation and T cell proliferation; and
meanwhile, cyclodextrin-based polymer could facilitate
CPT to inhibit tumor growth at early stage of tumorigen-
esis. CPT could be transported into brain by crossing the
blood-brain barrier (BBB), but as we known, cyclodextrin-
based polymer may not pass through the BBB. Therefore,
IT-101, which deliver CPT closing to the brain, may have
no adverse effect directly on central nervous system, and
focus on modulating the immune responses in peripherals.
Conjugated with cyclodextrin-based polymer may reduce
the adverse effects of CPT on peripheral tissues and effi-
ciently elevate bioavailability of CPT in brain. We expect
IT-101 may be used with other anti-cancer drugs to
achieve synergistic suppression of tumor growth. Recent
clinical studies highlight the efficacy of PD-1 and PD-L1
duo inhibition as a promising anti-tumor therapeutic strat-
egy [50, 51]. PD-1/PD-L1 inhibits T cell survival, prolifera-
tion, cytotoxicity and cytokine secretion, protection of
tumors from attacking of cytotoxic T cells, and induction
of cell death in tumor-specific T lymphocytes [52–55]. Im-
mune checkpoint inhibitors (antibodies against PD-1/PD-
L1 or CLTA-4) modulate the host’s own immune
responses to attack tumor tissues, even the brain metasta-
ses [56, 57]. Hence, combined treatment of IT-101 with
PD-1/PD-L1 blocker may be an interesting therapeutic
strategy, since IT-101 treatment can induce effected NK
cells to facilitate T cell activation, and blocking of PD-1/
PD-L1 can subsequently promote T cell proliferation and
activation. Upon breakdown of immune surveillance of tu-
mors by IT-101, CPT can then target and inhibit tumor
cell proliferation.
Fig. 6 IT-101 induced activation of NK cells, which facilitates other immune cells to attack tumors. First immunization with IT-101 (CPT conjugated
with CD-PEG) modulated the populations of neutrophil (Neu) and immature dendritic cells (iDC). Boosting with IT-101 induced affected NK cells
to secrete IFNγ and TNFα. IFNγ promotes Th and Tc cell activation, and TNFα induces dendritic cell (DC) migration. Both NK and Tc cells generate
and secrete perforin and granzyme to weaken and destroy tumor cells. Black lines indicate the results we suggested in this study. Gray lines
indicate the results we predicted based on our results
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12929-019-0583-0.
Additional file 1: Fig. S1. Working schemes for immunological analysis
of nanoparticle IT-101 in mice. Fig. S2. Significant changes after 16 h IT-
101 treatment were presented by dot plots. Fig. S3. Cytokine assay. Fig.
S4. Changes of cytokine expression after CPT treatment. Fig. S5. Signifi-
cant changes after 216 h treatment were presented by dot plots. Fig. S6.
Early stage of tumorigenesis in F1B transgenic mice.
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Nanoparticles have the potential advantage of targeting specific cell types
within organs, while the immune responses related to nanoparticles have
become safety issues of importance. The potentially facilitated effects for
immune therapy are also a critical investigated part of nanoparticles.
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